NCT03332576

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Phase 1b Study of Extended Dosing of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.) · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.

Conditions

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	DPX-Survivac	SubQ injection
BIOLOGICAL	DPX-Survivac(Aqueous)	SubQ injection
DRUG	Cyclophosphamide	PO BID

Timeline

• Start date: 2013-08-23
• Primary completion: 2016-09-08
• Completion: 2019-09-09
• First posted: 2017-11-06
• Last updated: 2021-06-18

Locations

3 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study